RGEN · NASDAQ
Repligen (RGEN) Stock Price & Fundamentals
Repligen (RGEN) closed at $845.17 on Oct 9, 2026, down 0.04% from the previous close of $845.47.
Share price, past year
1Y +36.19%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $845.17 |
| Sep 30, 2026 | $828.86 |
| Aug 31, 2026 | $796.05 |
| Jul 31, 2026 | $789.71 |
| Jun 30, 2026 | $773.62 |
| May 29, 2026 | $739.62 |
| Apr 30, 2026 | $723.74 |
| Mar 31, 2026 | $688.65 |
| Feb 27, 2026 | $672.36 |
| Jan 30, 2026 | $665.24 |
| Dec 31, 2025 | $664.89 |
| Nov 28, 2025 | $660.98 |
| Oct 31, 2025 | $627.34 |
Key statistics
- Market cap
- $47.69B
- P/E (TTM)
- 1,142.1
- EPS (TTM)
- $0.74
- Revenue (TTM)
- $785.10M
- Net income (TTM)
- $41.54M
- Shares outstanding
- 56.4M
- Dividend yield
- —
- 52-week range
- $603.03 – $848.38
Repligen's market cap is $47.69B, based on a share price of $845.17 and 56.4M shares outstanding as of Jun 30, 2026.
Financials
Repligen reported revenue of $738.26M for fiscal 2025, up 16.36% from fiscal 2024.
Repligen earned net income of $48.89M in fiscal 2025, a net margin of 6.6%.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $738.26M | +16.4% | $48.89M | 6.6% | $0.86 | $93.90M |
| FY2024ended Dec 31, 2024 | $634.44M | +0.3% | −$25.51M | −4.0% | −$0.46 | $149.72M |
| FY2023ended Dec 31, 2023 | $632.36M | −21.1% | $35.60M | 5.6% | $0.63 | $77.70M |
| FY2022ended Dec 31, 2022 | $801.54M | +19.5% | $185.96M | 23.2% | $3.24 | $87.25M |
| FY2021ended Dec 31, 2021 | $670.53M | +83.1% | $128.29M | 19.1% | $2.24 | $51.93M |
| FY2020ended Dec 31, 2020 | $366.26M | +35.5% | $59.93M | 16.4% | $1.11 | $40.17M |
| FY2019ended Dec 31, 2019 | $270.25M | +39.3% | $21.41M | 7.9% | $0.44 | $48.71M |
| FY2018ended Dec 31, 2018 | $194.03M | +37.4% | $16.62M | 8.6% | $0.37 | $22.14M |
| FY2017ended Dec 31, 2017 | $141.24M | +35.1% | $28.35M | 20.1% | $0.72 | $12.00M |
| FY2016ended Dec 31, 2016 | $104.54M | — | $11.68M | 11.2% | $0.34 | $3.20M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $204.13M | $5.01M | $0.09 |
| Q1 FY2026ended Mar 31, 2026 | $194.26M | $8.33M | $0.15 |
| Q4 FY2025ended Dec 31, 2025 | $197.91M | $13.29M | $0.24 |
| Q3 FY2025ended Sep 30, 2025 | $188.81M | $14.91M | $0.26 |
| Q2 FY2025ended Jun 30, 2025 | $182.37M | $14.87M | $0.26 |
| Q1 FY2025ended Mar 31, 2025 | $169.17M | $5.83M | $0.10 |
| Q4 FY2024ended Dec 31, 2024 | $167.55M | −$33.87M | −$0.61 |
| Q3 FY2024ended Sep 30, 2024 | $154.87M | −$654.00K | −$0.01 |
Company profile
- Name
- Repligen Corporation
- Ticker
- RGEN
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 41 Seyon Street, Building 1, Suite 100, Waltham, MA 02453
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0000730272
Recent SEC filings
- Oct 6, 2026
- Sep 15, 2026
- Sep 8, 2026
- Jul 29, 2026
- Jul 28, 2026
- Jul 22, 2026
- May 15, 2026
- May 6, 2026
Frequently asked questions
What is Repligen's stock price?
Repligen (RGEN) closed at $845.17 on Oct 9, 2026, down 0.04% from the previous close of $845.47.
What is Repligen's market cap?
Repligen's market cap is $47.69B, based on a share price of $845.17 and 56.4M shares outstanding as of Jun 30, 2026.
How much revenue does Repligen make?
Repligen reported revenue of $738.26M for fiscal 2025, up 16.36% from fiscal 2024.
What is RGEN's P/E ratio?
Repligen's price-to-earnings ratio is 1,142.1, based on trailing twelve-month diluted EPS of $0.74.
Does Repligen pay a dividend?
Repligen's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Repligen Corporation's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures